Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?

Bibliographic Details
Main Author:	Ranjan Gupta
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Journal of Postgraduate Medicine
Online Access:	http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2020;volume=66;issue=2;spage=116;epage=116;aulast=Gupta

Similar Items

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
by: B Oza, et al.
Published: (2019-01-01)

From generic to biosimilar drugs: why take an innovative pace?
by: Fereshteh Barei, et al.
Published: (2012-12-01)

Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal
by: Maria da Conceição Constantino Portela, et al.
Published: (2017-03-01)

Why are biosimilars much more complex than generics?
by: Eduardo Pagani

Generic drugs and pharmacovigilance
by: Nelson Santiago Vispo
Published: (2017-11-01)

Generics and biosimilars in oncology
by: I. A. Gopienko, et al.
Published: (2020-04-01)

Entry strategies into biosimilars: assessment of entry modes into the field of biosimilars from the perspective of pharmaceuticals, generics and biologics companies
by: Von Gehren, August Levin
Published: (2013)

Generic and biosimilar medicines: quid?
by: Steven Simoens
Published: (2012-12-01)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
by: Ioanna Spanou, et al.
Published: (2019-07-01)

Innovative Biologics, Biosimilars and Biobetters: Development of Biopharma Industry in Taiwan
by: Wang, Ren-Hong, et al.
Published: (2018)

The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond
by: Lin-Chau Chang
Published: (2019-07-01)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
by: Erik Doevendans, et al.
Published: (2019-03-01)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
by: Arnold G. Vulto
Published: (2019-12-01)

Biologicals versus biosimilars the future ahead
by: A Singhal, et al.
Published: (2015-01-01)

A Study of the Doctrine of Equivalence on Biosimilars Based on the Patent Infringement in the context of Generics –From U.S. Perspectives
by: Shen , Yea Huei, et al.
Published: (2016)

Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

From Biologics to Biosimilars and Biobetters - Democratization of High-end Therapeutics
by: Santosh G Honavar
Published: (2021-01-01)

Biosimilars: Company Strategies to Capture Value from the Biologics Market
by: Juan Leonardo Martínez-Hurtado, et al.
Published: (2012-12-01)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
by: Carlos A. López-Morales, et al.
Published: (2015-01-01)

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab
by: Shiwei Miao, et al.
Published: (2017-01-01)

A Study on the Pharmaceutical Products Approval Regulation and Patent Protection: The Development of Legislation from Generic Drug to Biosimilar
by: Yang, Fu Ching, et al.

Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
by: Caterina Palleria, et al.
Published: (2018-01-01)

The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
by: Davide Mazzoni, et al.
Published: (2021-01-01)

A Study of the Law and Regulation on Biosimilar Drugs Based on the Development of the Law and Regulation on Generic Drugs — From the U.S. Perspectives
by: Hsuan-HsiungWang, et al.
Published: (2011)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Pharmacoenvironmentology – a component of pharmacovigilance
by: Gupta Varun, et al.
Published: (2007-07-01)

Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!
by: Concepcion Castillo-Gallego, et al.
Published: (2020-01-01)

Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia
by: Graham-Clarke PL, et al.
Published: (2020-06-01)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01)

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
by: Eva Rahman Kabir, et al.
Published: (2019-08-01)

Pharmacovigilance in India
by: Sarita Mulkalwar, et al.
Published: (2013-01-01)

ON THE SUBJECT OF PHARMACOVIGILANCE
by: M. A. Murashko
Published: (2015-09-01)

ON THE SUBJECT OF PHARMACOVIGILANCE
by: M. A. Murashko
Published: (2015-09-01)

Estudos de medicamentos biosimilares Studies on biosimilar medications
by: Winston Bonetti Yoshida
Published: (2010-09-01)

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
by: Airaksinen, M., et al.
Published: (2022)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)